Sinomenine Hydrochloride Protects IgA Nephropathy Through Regulating Cell Growth and Apoptosis of T and B Lymphocytes

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Apr 22

PMID 38645988

Authors

Jun-Jian Li

Li Li

Shuang Li

Xin-Yi Tang

Hui-Feng Sun

Jian-Xin Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: Sinomenine hydrochloride (SH) is used to treat chronic inflammatory diseases such as rheumatoid arthritis and may also be efficacious against Immunoglobulin A nephropathy (IgAN). However, no trial has investigated the molecular mechanism of SH on IgAN. Therefore, this study aims to investigate the effect and mechanism of SH on IgAN.

Methods: The pathological changes and IgA and C3 depositions in the kidney of an IgAN rat model were detected by periodic acid-Schiff (PAS) and direct immunofluorescence staining. After extracting T and B cells using immunomagnetic beads, we assessed their purity, cell cycle phase, and apoptosis stage through flow cytometry. Furthermore, we quantified cell cycle-related and apoptosis-associated proteins by Western blotting.

Results: SH reduced IgA and C3 depositions in stage 4 IgAN, thereby decreasing inflammatory cellular infiltration and mesangial injury in an IgAN model induced using heteroproteins. Furthermore, SH arrested the cell cycle of lymphocytes T and B from the spleen of IgAN rats. Regarding the mechanism, our results demonstrated that SH regulated the Cyclin D1 and Cyclin E1 protein levels for arresting the cell cycle and it also regulated Bax and Bcl-2 protein levels, thus increasing Cleaved caspase-3 protein levels in Jurkat T and Ramos B cells.

Conclusion: SH exerts a dual regulation on the cell cycle and apoptosis of T and B cells by controlling cell cycle-related and apoptosis-associated proteins; it also reduces inflammatory cellular infiltration and mesangial proliferation. These are the major mechanisms of SH in IgAN.

References

Vaz de Castro P, Bitencourt L, Pereira B, Lima A, Hermida H, Moreira Neto C . Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children. Pediatr Nephrol. 2021; 37(3):499-508. DOI: 10.1007/s00467-021-05316-0. View

Zhu L, Dai L, Shen H, Gu P, Zheng K, Liu Y . Qing Chang Hua Shi granule ameliorate inflammation in experimental rats and cell model of ulcerative colitis through MEK/ERK signaling pathway. Biomed Pharmacother. 2019; 116:108967. DOI: 10.1016/j.biopha.2019.108967. View

Zhang T, Ouyang X, Gou S, Zhang Y, Yan N, Chang L . Novel synovial targeting peptide-sinomenine conjugates as a potential strategy for the treatment of rheumatoid arthritis. Int J Pharm. 2022; 617:121628. DOI: 10.1016/j.ijpharm.2022.121628. View

Yang J, Sarwal R, Fervenza F, Sarwal M, Lafayette R . Noninvasive Urinary Monitoring of Progression in IgA Nephropathy. Int J Mol Sci. 2019; 20(18). PMC: 6770813. DOI: 10.3390/ijms20184463. View

Chang S, Li X . The Role of Immune Modulation in Pathogenesis of IgA Nephropathy. Front Med (Lausanne). 2020; 7:92. PMC: 7105732. DOI: 10.3389/fmed.2020.00092. View

Weiberg D, Basic M, Smoczek M, Bode U, Bornemann M, Buettner M . Participation of the spleen in the IgA immune response in the gut. PLoS One. 2018; 13(10):e0205247. PMC: 6171922. DOI: 10.1371/journal.pone.0205247. View

Xie X, Liu P, Gao L, Zhang X, Lan P, Bijol V . Renal deposition and clearance of recombinant poly-IgA complexes in a model of IgA nephropathy. J Pathol. 2021; 254(2):159-172. PMC: 8324010. DOI: 10.1002/path.5658. View

Ruszkowski J, Lisowska K, Pindel M, Heleniak Z, Debska-Slizien A, Witkowski J . T cells in IgA nephropathy: role in pathogenesis, clinical significance and potential therapeutic target. Clin Exp Nephrol. 2018; 23(3):291-303. PMC: 6394565. DOI: 10.1007/s10157-018-1665-0. View

Zhao J, Liu H . Mechanism for the therapeutic effect of preparations on IgA nephropathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(5):573-582. PMC: 10929912. DOI: 10.11817/j.issn.1672-7347.2022.210410. View

10.

Ka S, Hsieh T, Lin S, Yang S, Wu C, Sytwu H . Decoy receptor 3 inhibits renal mononuclear leukocyte infiltration and apoptosis and prevents progression of IgA nephropathy in mice. Am J Physiol Renal Physiol. 2011; 301(6):F1218-30. DOI: 10.1152/ajprenal.00050.2011. View

11.

Liu Y, Sun Y, Zhou Y, Tang X, Wang K, Ren Y . Sinomenine hydrochloride inhibits the progression of plasma cell mastitis by regulating IL-6/JAK2/STAT3 pathway. Int Immunopharmacol. 2019; 81:106025. DOI: 10.1016/j.intimp.2019.106025. View

12.

Lee G, Hwang K, Choi K . Effects of Fludioxonil on the Cell Growth and Apoptosis in T and B Lymphocytes. Biomolecules. 2019; 9(9). PMC: 6770511. DOI: 10.3390/biom9090500. View

13.

Fellstrom B, Barratt J, Cook H, Coppo R, Feehally J, De Fijter J . Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017; 389(10084):2117-2127. DOI: 10.1016/S0140-6736(17)30550-0. View

14.

Floege J, Rauen T, Tang S . Current treatment of IgA nephropathy. Semin Immunopathol. 2021; 43(5):717-728. PMC: 8551131. DOI: 10.1007/s00281-021-00888-3. View

15.

Taylor S, Pieri K, Nanni P, Tica J, Barratt J, Didangelos A . Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA nephropathy and is associated with IgA-positive B-cells in affected kidneys. J Autoimmun. 2019; 105:102309. DOI: 10.1016/j.jaut.2019.102309. View

16.

Panos G, Boeckler F . Statistical Analysis in Clinical and Experimental Medical Research: Simplified Guidance for Authors and Reviewers. Drug Des Devel Ther. 2023; 17:1959-1961. PMC: 10328100. DOI: 10.2147/DDDT.S427470. View

17.

Gesualdo L, Di Leo V, Coppo R . The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021; 43(5):657-668. PMC: 8551125. DOI: 10.1007/s00281-021-00871-y. View

18.

Park J, Kim T, Oh B, Cho H, Kim J, Yoo S . Comparative analysis of the tonsillar microbiota in IgA nephropathy and other glomerular diseases. Sci Rep. 2020; 10(1):16206. PMC: 7530979. DOI: 10.1038/s41598-020-73035-x. View

19.

Thompson A, Carroll K, Inker L, Floege J, Perkovic V, Boyer-Suavet S . Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019; 14(3):469-481. PMC: 6419287. DOI: 10.2215/CJN.08600718. View

20.

Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J . Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2022; 103(2):391-402. DOI: 10.1016/j.kint.2022.09.017. View